A novel multi epitope chimeric vaccine design that integrates pan genomics and reverse vaccine science, completely changing and identifying the vaccine targets of Brucella
Description
A total of 89 Brucella proteomes were obtained from the NCBI database. For detailed information such as login numbers, microbial names, and genome upload times, please refer to Supplementary Data Sheet S1. The IPGA pan genomic analysis tool identified 2716 core genes of Brucella, for detailed information, please refer to Supplementary Data Sheet S2. The results of the subtractive proteomics study showed that out of 2716 core proteins, there are 1414 bacterial essential proteins, 1388 human non homologous proteins, 471 virulence proteins, and 121 antibiotic resistance proteins. For additional details, please refer to Supplementary Data Sheet S3 to S6. Predictions concerning the transmembrane domain, signal sequence, and 3D structure of the candidate antigen are presented in Supplementary Figures 1 and 2. Additionally, the quality validation results of MHC II molecular modeling conducted through the SWISS-MODEL server have been provided as shown in Supplementary Figures 3, 4 and 5. Supplementary Figures 6, 7 and 8 show the amino acid residues involved in the interaction between T cell epitopes and MHC molecules. This type of signal peptide is usually associated with bacterial protein secretion, and due to the absence of transmembrane helices, the vaccine does not encounter significant obstacles when expressed in vivo(Supplementary Figures 9 and 10). Additionally, data from the PDBsum server reveals that the vaccine consists of 2 sheets, 3 beta hairpins, 5 beta bulbs, 6 strands, 19 helices, 31 helix-helix interacs, 15 beta turns, 7 gamma turns, and 1 disulfide, as shown in Supplementary Figure 11. Population coverage information for other regions are available in Supplementary Table 1. The cDNA length of the vaccine was optimized to 1122 bps with a stop codon appended at the end (Supplementary Data 3.1). The vaccine displays a codon adaptation index (CAI) of 0.93 and GC content of 53.74%, both of which suggest high gene expression potential and robust expression capability in E.coli (K12 strain). Obtain mRNA sequences of vaccines using transcription and translation tools (Supplementary Data 3.2).